Method-Comparison Validation of a Novel Capillary Blood Collection Kit, True Dose<sup>®</sup> TD-EPI, for Therapeutic Drug Monitoring of Epirubicin
De Chiara et al.
The finding, in our words
The True Dose TD-EPI kit demonstrated strong analytical agreement with venous blood for epirubicin monitoring, and the capillary samples remained stable for 72 hours at ambient temperature.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Capillary blood collected with the Mitra® device showed correlation with venous samples for paclitaxel therapeutic drug monitoring, but wide confidence intervals suggest the methods may not be interchangeable. While plasma and whole blood concentrations were more closely aligned, the variability raises questions about using self-collected capillary samples for dose individualisation without further validation.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
The homeRNA capillary blood collection and stabilization platform successfully captured lipopolysaccharide-induced inflammatory gene expression profiles. These transcriptomic responses were comparable to those obtained from traditional venous blood samples stabilized with RNAlater or PAXgene, demonstrating the platform's suitability for remote transcriptomic monitoring.
This study validated a method requiring only 10 microlitres of serum and found high agreement between fingerstick capillary samples and venous serum for monitoring twelve antibiotics. The results suggest capillary serum sampling is a feasible, minimally invasive alternative that avoids the haematocrit effect associated with whole blood microsampling.
The study found volumetric absorptive microsampling showed high agreement between capillary and venous concentrations, with 94% of dasatinib and 95% of imatinib samples meeting the 20% acceptance criterion. VAMS is viable for imatinib monitoring and may allow longitudinal follow-up for dasatinib; however, VAMS results for imatinib, but not dasatinib, could be converted to plasma concentrations using prior ratios.